A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening

Experimental Biology and Medicine

Volumn 239, Issue 9, 2014, Pages 1240-1254

  Heylman, Christopher ^a,b   Sobrino, Agua ^b   Shirure, Venktesh S ^a,b   Hughes, Christopher CW ^a,b   George, Steven C ^a,b,c  

^a University of California at Irvine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anticancer drugs; bone marrow; cardiac tissue; Three dimensional microphysiological systems; tumor; vasculature

Indexed keywords

ADRENALIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; DOCETAXEL; DOFETILIDE; DOXORUBICIN; DRUG METABOLIZING ENZYME; ETOPOSIDE; FIBRONECTIN; FLUOROURACIL; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 1; LAMININ; MILTEFOSINE; NAVELBINE; NEW DRUG; NITRIC OXIDE; PACLITAXEL; PERTUZUMAB; PROPRANOLOL; RAPAMYCIN; TAMOXIFEN; TIRAPAZAMINE; TRASTUZUMAB; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; BONE MARROW; BONE MARROW TOXICITY; CAPILLARY; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; DRUG EFFICACY; DRUG SCREENING; DRUG TOXICITY; HEART MUSCLE; HIGH THROUGHPUT SCREENING; MICROTECHNOLOGY; MICROVASCULATURE; MORBIDITY; MORTALITY; NEOPLASM; NUTRIENT; PHYSIOLOGY; PLURIPOTENT STEM CELL; TISSUE ENGINEERING; TUMOR GROWTH; VALIDATION PROCESS; WASTE COMPONENT REMOVAL; ANTICANCER DRUGS; CULTURE TECHNIQUE; EQUIPMENT; HEART; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; REVIEW; THREE-DIMENSIONAL MICROPHYSIOLOGICAL SYSTEMS; VASCULARIZATION;

ANTICANCER DRUGS; BONE MARROW; CARDIAC TISSUE; THREE-DIMENSIONAL MICROPHYSIOLOGICAL SYSTEMS; TUMOR; VASCULATURE;

CELL CULTURE TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; PLURIPOTENT STEM CELLS; TISSUE ENGINEERING;

EID: 84907009889     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214525295     Document Type: Article

References (132)

1. Marsh JC.The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: A review.Cancer Res. 1976;36:1853-82
2. Dempke W,Von Poblozki A,Grothey A,Schmoll HJ.Human hematopoietic growth factors: Old lessons and new perspectives.Anticancer Res. 2000;20:5155-64
3. Testa NG,Hendry JH,Molineux G.Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy.Anticancer Res. 1985;5:101-10
4. Albini A,Pennesi G,Donatelli F,Cammarota R,De Flora S,Noonan DM.Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention.J Natl Cancer Inst. 2010;102:14-25
5. Hedhli N,Russell KS.Cardiotoxicity of molecularly targeted agents.Curr Cardiol Rev. 2011;7:221-33
6. Todaro MC, Oreto L, Qamar R, Paterick TE, Carerj S, Khandheria BK. Cardioncology: State of the heart. Int J Cardiol 2013;168:680–7.
7. Griffith LG,Swartz MA.Capturing complex 3D tissue physiology in vitro.Nat Rev Mol Cell Biol. 2006;7:211-24
8. Lo AT,Mori H,Mott J,Bissell MJ.Constructing three-dimensional models to study mammary gland branching morphogenesis and functional differentiation.J Mammary Gland Biol Neoplasia. 2012;17:103-10
9. Roskelley CD,Desprez PY,Bissell MJ.Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction.Proc Natl Acad Sci USA. 1994;91:12378-82
10. Schyschka L,Sanchez JJ,Wang Z,Burkhardt B,Muller-Vieira U,Zeilinger K,Bachmann A,Nadalin S,Damm G,Nussler AK.Hepatic 3D cultures but not 2D cultures preserve specific transporter activity for acetaminophen-induced hepatotoxicity.Arch Toxicol. 2013;87:1581-93
11. Dalen H,Burki HJ.Some observations on the three-dimensional growth of L5178Y cell colonies in soft agar culture.Exp Cell Res. 1971;65:433-8
12. Feder-Mengus C,Ghosh S,Reschner A,Martin I,Spagnoli GC.New dimensions in tumor immunology: What does 3D culture reveal?.Trends Mol Med. 2008;14:333-40
13. Wang F,Weaver VM,Petersen OW,Larabell CA,Dedhar S,Briand P,Lupu R,Bissell MJ.Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: A different perspective in epithelial biology.Proc Natl Acad Sci USA. 1998;95:14821-6
14. Valcarcel M,Arteta B,Jaureguibeitia A,Lopategi A,Martinez I,Mendoza L,Muruzabal FJ,Salado C,Vidal-Vanaclocha F.Three-dimensional growth as multicellular spheroid activates the proangiogenic phenotype of colorectal carcinoma cells via LFA-1-dependent VEGF: Implications on hepatic micrometastasis.J Transl Med. 2008;6:57-57
15. Wozniak MA,Modzelewska K,Kwong L,Keely PJ.Focal adhesion regulation of cell behavior.Biochim Biophys Acta. 2004;1692:103-19
16. Yamazaki D,Kurisu S,Takenawa T.Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates.Oncogene. 2009;28:1570-83
17. Beningo KA,Dembo M,Wang YL.Responses of fibroblasts to anchorage of dorsal extracellular matrix receptors.Proc Natl Acad Sci USA. 2004;101:18024-9
18. Horning JL,Sahoo SK,Vijayaraghavalu S,Dimitrijevic S,Vasir JK,Jain TK,Panda AK,Labhasetwar V.3-D tumor model for in vitro evaluation of anticancer drugs.Mol Pharm. 2008;5:849-62
19. Doublier S,Belisario DC,Polimeni M,Annaratone L,Riganti C,Allia E,Ghigo D,Bosia A,Sapino A.HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: A potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.BMC Cancer. 2012;12:4-4
20. Chitcholtan K,Asselin E,Parent S,Sykes PH,Evans JJ.Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer.Exp Cell Res. 2013;319:75-87
21. Howes AL,Chiang GG,Lang ES,Ho CB,Powis G,Vuori K,Abraham RT.The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.Mol Cancer Ther. 2007;6:2505-14
22. Weigelt B,Lo AT,Park CC,Gray JW,Bissell MJ.HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.Breast Cancer Res Treat. 2010;122:35-43
23. Assadian S,El-Assaad W,Wang XQ,Gannon PO,Barres V,Latour M,Mes-Masson AM,Saad F,Sado Y,Dostie J,Teodoro JG.p53 inhibits angiogenesis by inducing the production of Arresten.Cancer Res. 2012;72:1270-9
24. Millerot-Serrurot E,Guilbert M,Fourre N,Witkowski W,Said G,Van Gulick L,Terryn C,Zahm JM,Garnotel R,Jeannesson P.3D collagen type I matrix inhibits the antimigratory effect of doxorubicin.Cancer Cell Int. 2010;10:26-26
25. Carmeliet P,Jain RK.Angiogenesis in cancer and other diseases.Nature. 2000;407:249-57
26. Helmlinger G,Yuan F,Dellian M,Jain RK.Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation.Nat Med. 1997;3:177-82
27. Muschler GF,Nakamoto C,Griffith LG.Engineering principles of clinical cell-based tissue engineering.J Bone Joint Surg Am. 2004;86-A:1541-58
28. Zhang J,Friedman MH.Adaptive response of vascular endothelial cells to an acute increase in shear stress magnitude.Am J Physiol Heart Circ Physiol. 2012;302:H983-91
29. Cines DB,Pollak ES,Buck CA,Loscalzo J,Zimmerman GA,McEver RP,Pober JS,Wick TM,Konkle BA,Schwartz BS,Barnathan ES,McCrae KR,Hug BA,Schmidt AM,Stern DM.Endothelial cells in physiology and in the pathophysiology of vascular disorders.Blood. 1998;91:3527-61
30. Johnson JI,Decker S,Zaharevitz D,Rubinstein LV,Venditti JM,Schepartz S,Kalyandrug S,Christian M,Arbuck S,Hollingshead M,Sausville EA.Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.Br J Cancer. 2001;84:1424-31
31. Che ZM,Jung TH,Choi JH,Yoon DJ,Jeong HJ,Lee EJ,Kim J.Collagen-based co-culture for invasive study on cancer cells-fibroblasts interaction.Biochem Biophys Res Commun. 2006;346:268-75
32. Sutherland RM,Mccredie JA,Inch WR.Growth of multicell spheroids in tissue culture as a model of nodular carcinomas.J Natl Cancer Inst. 1971;46:113-20
33. Tanaka R,Saito T,Ashihara K,Nishimura M,Mizumoto H,Kudo R.Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.Gynecol Oncol. 2003;90:297-304
34. Jain RK.Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy.Science. 2005;307:58-62
35. Jain RK.Antiangiogenic therapy for cancer: Current and emerging concepts.Oncology (Williston Park). 2005;19:7-16
36. Leu AJ,Berk DA,Lymboussaki A,Alitalo K,Jain RK.Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation.Cancer Res. 2000;60:4324-7
37. Padera TP,Kadambi A,di Tomaso E,Carreira CM,Brown EB,Boucher Y,Choi NC,Mathisen D,Wain J,Mark EJ,Munn LL,Jain RK.Lymphatic metastasis in the absence of functional intratumor lymphatics.Science. 2002;296:1883-6
38. Jain RK.Barriers to drug-delivery in solid tumors.Sci Am. 1994;271:58-65
39. Rutkowski JM,Swartz MA.A driving force for change: Interstitial flow as a morphoregulator.Trends Cell Biol. 2007;17:44-50
40. Jain RK.Transport of molecules, particles, and cells in solid tumors.Annu Rev Biomed Eng. 1999;1:241-63
41. Hockel M,Vaupel P.Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects.J Natl Cancer Inst. 2001;93:266-76
42. Minchinton AI,Tannock IF.Drug penetration in solid tumours.Nat Rev Cancer. 2006;6:583-92
43. Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J, Schemmer P, Buchler MW, Herr I. Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS One 2012;7.
44. Comerford KM,Wallace TJ,Karhausen J,Louis NA,Montalto MC,Colgan SP.Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.Cancer Res. 2002;62:3387-94
45. Hsu YH,Moya ML,Abiri P,Hughes CC,George SC,Lee AP.Full range physiological mass transport control in 3D tissue cultures.Lab Chip. 2013;13:81-9
46. Kim S,Lee H,Chung M,Jeon NL.Engineering of functional, perfusable 3D microvascular networks on a chip.Lab Chip. 2013;13:1489-500
47. Moya ML,Hsu YH,Lee AP,Hughes CCW,George SC.In vitro perfused human capillary networks.Tissue Eng Part C Methods. 2013;19:730-7
48. Wiig H,Swartz MA.Interstitial fluid and lymph formation and transport: Physiological regulation and roles in inflammation and cancer.Physiol Rev. 2012;92:1005-60
49. Levental KR,Yu HM,Kass L,Lakins JN,Egeblad M,Erler JT,Fong SFT,Csiszar K,Giaccia A,Weninger W,Yamauchi M,Gasser DL,Weaver VM.Matrix crosslinking forces tumor progression by enhancing integrin signaling.Cell. 2009;139:891-906
50. Egeblad M,Nakasone ES,Werb Z.Tumors as organs: Complex tissues that interface with the entire organism.Dev Cell. 2010;18:884-901
51. Schedin P,Mitrenga T,McDaniel S,Kaeck M.Mammary ECM composition and function are altered by reproductive state.Mol Carcinog. 2004;41:207-20
52. Fleming JM, Miller TC, Quinones M, Xiao Z, Xu X, Meyer MJ, Ginsburg E, Veenstra TD, Vonderhaar BK. The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo. BMC Med 2010;8.
53. Lin EY,Li JF,Gnatovskiy L,Deng Y,Zhu L,Grzesik DA,Qian H,Xue XN,Pollard JW.Macrophages regulate the angiogenic switch in a mouse model of breast cancer.Cancer Res. 2006;66:11238-46
54. Kalluri R,Zeisberg M.Fibroblasts in cancer.Nat Rev Cancer. 2006;6:392-401
55. Chen XF,Aledia AS,Popson SA,Him L,Hughes CCW,George SC.Rapid anastomosis of endothelial progenitor cell-derived vessels with host vasculature is promoted by a high density of cotransplanted fibroblasts.Tissue Eng Part A. 2010;16:585-94
56. De Palma M,Lewis CE.Cancer macrophages limit chemotherapy.Nature. 2011;472:303-4
57. Colombo A,Cipolla C,Beggiato M,Cardinale D.Cardiac toxicity of anticancer agents.Curr Cardiol Rep. 2013;15:362-362
58. Ewer MS,Ewer SM.Cardiotoxicity of anticancer treatments: What the cardiologist needs to know.Nat Rev Cardiol. 2010;7:564-75
59. Raschi E,Vasina V,Ursino MG,Boriani G,Martoni A,De Ponti F.Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.Pharmacol Ther. 2010;125:196-218
60. Yeh ET,Bickford CL.Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management.J Am Coll Cardiol. 2009;53:2231-47
61. Monsuez JJ,Charniot JC,Vignat N,Artigou JY.Cardiac side-effects of cancer chemotherapy.Int J Cardiol. 2010;144:3-15
62. Bonita R,Pradhan R.Cardiovascular toxicities of cancer chemotherapy.Semin Oncol. 2013;40:156-67
63. French KM,Boopathy AV,DeQuach JA,Chingozha L,Lu H,Christman KL,Davis ME.A naturally derived cardiac extracellular matrix enhances cardiac progenitor cell behavior in vitro.Acta Biomater. 2012;8:4357-64
64. Das B,Antoon R,Tsuchida R,Lotfi S,Morozova O,Farhat W,Malkin D,Koren G,Yeger H,Baruchel S.Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth.Neoplasia. 2008;10:1105-19
65. Saloustros E,Tryfonidis K,Georgoulias V.Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.Expert Opin Pharmacother. 2011;12:851-63
66. Randall TD,Weissman IL.Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment.Blood. 1997;89:3596-606
67. Hsu YH,Moya ML,Abiri P,Hughes CC,George SC,Lee AP.Full range physiological mass transport control in 3D tissue cultures.Lab Chip. 2013;13:81-9
68. Moya ML, Hsu YH, Lee AP, Hughes CC, George SC. In vitro perfused human capillary networks. Tissue Eng Part C Methods 2013;19:730–7.
69. Hsu YH, Moya ML, Hughes CC, George SC, Lee AP. A microfluidic platform for generating large-scale nearly identical human microphysiological vascularized tissue arrays. Lab Chip 2013;13:2990–8.
70. Malavia NK,Raub CB,Mahon SB,Brenner M,Panettieri RA,George SC.Airway epithelium stimulates smooth muscle proliferation.Am J Respir Cell Mol Biol. 2009;41:297-304
71. Griffith CK,Miller C,Sainson RC,Calvert JW,Jeon NL,Hughes CC,George SC.Diffusion limits of an in vitro thick prevascularized tissue.Tissue Eng. 2005;11:257-66
72. Thompson HG,Mih JD,Krasieva TB,Tromberg BJ,George SC.Epithelial-derived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasis.Am J Physiol Lung Cell Mol Physiol. 2006;291:L1277-85
73. Wikswo JP,Block FE,Cliffel DE,Goodwin CR,Marasco CC,Markov DA,McLean DL,McLean JA,McKenzie JR,Reiserer RS,Samson PC,Schaffer DK,Seale KT,Sherrod SD.Engineering challenges for instrumenting and controlling integrated organ-on-chip systems.IEEE Trans Biomed Eng. 2013;60:682-90
74. Wikswo JP,Curtis EL,Eagleton ZE,Evans BC,Kole A,Hofmeister LH,Matloff WJ.Scaling and systems biology for integrating multiple organs-on-a-chip.Lab Chip. 2013;13:3496-511
75. Williams LR,Leggett RW.Reference values for resting blood flow to organs of man.Clin Phys Physiol Meas. 1989;10:187-217
76. Stringari C,Cinquin A,Cinquin O,Digman MA,Donovan PJ,Gratton E.Phasor approach to fluorescence lifetime microscopy distinguishes different metabolic states of germ cells in a live tissue.Proc Natl Acad Sci USA. 2011;108:13582-7
77. Chen TW,Wardill TJ,Sun Y,Pulver SR,Renninger SL,Baohan A,Schreiter ER,Kerr RA,Orger MB,Jayaraman V,Looger LL,Svoboda K,Kim DS.Ultrasensitive fluorescent proteins for imaging neuronal activity.Nature. 2013;499:295-300
78. Itzhaki I,Rapoport s,Huber I,Mizrahi I,Zwi-Dantsis L,Arbel G,Schiller J,Gepstein L.Calcium handling in human induced pluripotent stem cell derived cardiomyocytes.PLoS One. 2011;6:e18037-e18037
79. Yan P,Acker CD,Zhou WL,Lee P,Bollensdorff C,Negrean A,Lotti J,Sacconi L,Antic SD,Kohl P,Mansvelder HD,Pavone FS,Loew LM.Palette of fluorinated voltage-sensitive hemicyanine dyes.Proc Natl Acad Sci USA. 2012;109:20443-8
80. Xi J,Khalil M,Shishechian N,Hannes T,Pfannkuche K,Liang H,Fatima A,Haustein M,Suhr F,Bloch W,Reppel M,Saric T,Wernig M,Janisch R,Brockmeier K,Hescheler J,Pillekamp F.Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells.FASEB J. 2010;24:2739-51
81. Gibson RJ,Bowen JM.Biomarkers of regimen-related mucosal injury.Cancer Treat Rev. 2011;37:487-93
82. Xue H,Sawyer MB,Wischmeyer PE,Baracos VE.Nutrition modulation of gastrointestinal toxicity related to cancer chemotherapy: From preclinical findings to clinical strategy.JPEN J Parenter Enteral Nutr. 2011;35:74-90
83. Maor Y,Malnick S.Liver injury induced by anticancer chemotherapy and radiation therapy.Int J Hepatol. 2013;2013:815105-815105
84. Pabla N,Dong Z.Curtailing side effects in chemotherapy: A tale of PKCdelta in cisplatin treatment.Oncotarget. 2012;3:107-11
85. Argyriou AA,Bruna J,Marmiroli P,Cavaletti G.Chemotherapy-induced peripheral neurotoxicity (CIPN): An update.Crit Rev Oncol Hematol. 2012;82:51-77
86. Cavaletti G,Marmiroli P.Chemotherapy-induced peripheral neurotoxicity.Nat Rev Neurol. 2010;6:657-66
87. Gilliam LA,St Clair DK.Chemotherapy-induced weakness and fatigue in skeletal muscle: The role of oxidative stress.Antioxid Redox Signal. 2011;15:2543-63
88. van Norren K,van Helvoort A,Argiles JM,van Tuijl S,Arts K,Gorselink M,Laviano A,Kegler D,Haagsman HP,van der Beek EM.Direct effects of doxorubicin on skeletal muscle contribute to fatigue.Br J Cancer. 2009;100:311-4
89. Blumenfeld Z.Chemotherapy and fertility.Best Pract Res Clin Obstet Gynaecol. 2012;26:379-90
90. Ragheb AM,Sabanegh ES.Male fertility-implications of anticancer treatment and strategies to mitigate gonadotoxicity.Anticancer Agents Med Chem. 2010;10:92-102
91. Hoekstra R,Nibourg GA,van der Hoeven TV,Plomer G,Seppen J,Ackermans MT,Camus S,Kulik W,van Gulik TM,Elferink RP,Chamuleau RA.Phase 1 and phase 2 drug metabolism and bile acid production of HepaRG cells in a bioartificial liver in absence of dimethyl sulfoxide.Drug Metab Dispos. 2013;41:562-7
92. Hilmer SN,Shenfield GM,Le Couteur DG.Clinical implications of changes in hepatic drug metabolism in older people.Ther Clin Risk Manag. 2005;1:151-6
93. Jang KJ,Mehr AP,Hamilton GA,McPartlin LA,Chung S,Suh KY,Ingber DE.Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment.Integr Biol (Camb). 2013;5:1119-29
94. Ould-Dris A,Paullier P,Griscom L,Legallais C,Leclerc E.Analysis of the mass transfers in an artificial kidney microchip.J Membr Sci. 2010;352:116-125
95. Naik P,Cucullo L.In vitro blood-brain barrier models: Current and perspective technologies.J Pharm Sci. 2012;101:1337-54
96. Pedersen BK.Muscles and their myokines.J Exp Biol. 2011;214:337-46
97. Al Moundhri MS,Al-Salam S,Al Mahrouqee A,Beegam S,Ali BH.The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: Some behavioral, biochemical, and histopathological studies.J Med Toxicol. 2013;9:25-33
98. Li CL,Tian T,Nan KJ,Zhao N,Guo YH,Cui J,Wang J,Zhang WG.Survival advantages of multicellular spheroids vs.monolayers of HepG2 cells in vitro. Oncol Rep. 2008;20:1465-71
99. David L,Dulong V,Le Cerf D,Cazin L,Lamacz M,Vannier JP.Hyaluronan hydrogel: An appropriate three-dimensional model for evaluation of anticancer drug sensitivity.Acta Biomater. 2008;4:256-63
100. Fujiwara D,Kato K,Nohara S,Iwanuma Y,Kajiyama Y.The usefulness of three-dimensional cell culture in induction of cancer stem cells from esophageal squamous cell carcinoma cell lines.Biochem Biophys Res Commun. 2013;434:773-8
101. Gurski LA,Jha AK,Zhang C,Jia X,Farach-Carson MC.Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells.Biomaterials. 2009;30:6076-85
102. Padron JM,van der Wilt CL,Smid K,Smitskamp-Wilms E,Backus HH,Pizao PE,Giaccone G,Peters GJ.The multilayered postconfluent cell culture as a model for drug screening.Crit Rev Oncol Hematol. 2000;36:141-57
103. Nirmalanandhan VS,Duren A,Hendricks P,Vielhauer G,Sittampalam GS.Activity of anticancer agents in a three-dimensional cell culture model.Assay Drug Dev Technol. 2010;8:581-90
104. Miyamoto H,Murakami T,Tsuchida K,Sugino H,Miyake H,Tashiro S.Tumor-stroma interaction of human pancreatic cancer: Acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins.Pancreas. 2004;28:38-44
105. Muerkoster S,Wegehenkel K,Arlt A,Witt M,Sipos B,Kruse ML,Sebens T,Kloppel G,Kalthoff H,Folsch UR,Schafer H.Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta.Cancer Res. 2004;64:1331-7
106. Serebriiskii I,Castello-Cros R,Lamb A,Golemis EA,Cukierman E.Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells.Matrix Biol. 2008;27:573-85
107. Goel S,Duda DG,Xu L,Munn LL,Boucher Y,Fukumura D,Jain RK.Normalization of the vasculature for treatment of cancer and other diseases.Physiol Rev. 2011;91:1071-121
108. Thorpe PE.Vascular targeting agents as cancer therapeutics.Clin Cancer Res. 2004;10:415-27
109. Peters GJ,Smitskamp-Wilms E,Smid K,Pinedo HM,Jansen G.Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.Cancer Res. 1999;59:5529-35
110. Hicks KO,Pruijn FB,Secomb TW,Hay MP,Hsu R,Brown JM,Denny WA,Dewhirst MW,Wilson WR.Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.J Natl Cancer Inst. 2006;98:1118-28
111. Agastin S,Giang UB,Geng Y,Delouise LA,King MR.Continuously perfused microbubble array for 3D tumor spheroid model.Biomicrofluidics. 2011;5:24110-24110
112. Chen SY,Hung PJ,Lee PJ.Microfluidic array for three-dimensional perfusion culture of human mammary epithelial cells.Biomed Microdevices. 2011;13:753-8
113. Masur K,Niggemann B,Zanker KS,Entschladen F.Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers.Cancer Res. 2001;61:2866-9
114. Pasquier E,Ciccolini J,Carre M,Giacometti S,Fanciullino R,Pouchy C,Montero MP,Serdjebi C,Kavallaris M,Andre N.Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: Implication in breast cancer treatment.Oncotarget. 2011;2:797-809
115. Doherty KR, Wappel RL, Talbert DR, Trusk PB, Moran DM, Kramer JW, Brown AM, Shell SA, Bacus S. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol 2013;272:245–55.
116. Dolderer JH,Schuldes H,Bockhorn H,Altmannsberger M,Lambers C,von Zabern D,Jonas D,Schwegler H,Linke R,Schroder UH.HERG1 gene expression as a specific tumor marker in colorectal tissues.Eur J Surg Oncol. 2010;36:72-7
117. Glassmeier G,Hempel K,Wulfsen I,Bauer CK,Schumacher U,Schwarz JR.Inhibition of HERG1 K+ channel protein expression decreases cell proliferation of human small cell lung cancer cells.Pflugers Arch. 2012;463:365-76
118. Mehta D,Malik AB.Signaling mechanisms regulating endothelial permeability.Physiol Rev. 2006;86:279-367
119. Ruoslahti E.Specialization of tumour vasculature.Nat Rev Cancer. 2002;2:83-90
120. Levesque JP,Winkler IG.It takes nerves to recover from chemotherapy.Nat Med. 2013;19:669-71
121. Schimmel KJ,Richel DJ,van den Brink RB,Guchelaar HJ.Cardiotoxicity of cytotoxic drugs.Cancer Treat Rev. 2004;30:181-91
122. Wang Y,Probin V,Zhou D.Cancer therapy-induced residual bone marrow injury – Mechanisms of induction and implication for therapy.Curr Cancer Ther Rev. 2006;2:271-9
123. Chatterjee K,Zhang J,Tao R,Honbo N,Karliner JS.Vincristine attenuates doxorubicin cardiotoxicity.Biochem Biophys Res Commun. 2008;373:555-60
124. Force T,Krause DS,Van Etten RA.Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.Nat Rev Cancer. 2007;7:332-44
125. Raschi E,De Ponti F.Cardiovascular toxicity of anticancer-targeted therapy: Emerging issues in the era of cardio-oncology.Intern Emerg Med. 2012;7:113-31
126. Ewer MS,Lippman SM.Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity.J Clin Oncol. 2005;23:2900-2
127. Telli ML,Hunt SA,Carlson RW,Guardino AE.Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility.J Clin Oncol. 2007;25:3525-33
128. Wouters BG,Koritzinsky M.Hypoxia signalling through mTOR and the unfolded protein response in cancer.Nat Rev Cancer. 2008;8:851-64
129. Shin DH,Chun YS,Lee DS,Huang LE,Park JW.Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.Blood. 2008;111:3131-6
130. Ellis L,Hammers H,Pili R.Targeting tumor angiogenesis with histone deacetylase inhibitors.Cancer Lett. 2009;280:145-53
131. Garber K.Angiogenesis inhibitors suffer new setback.Nat Biotechnol. 2002;20:1067-8
132. Kruzliak P,Kovacova G,Pechanova O.Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension.Angiogenesis. 2013;16:289-95